COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

Learn more

Latest COVAX news

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.

The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022

COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.

Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.

Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…

The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…

Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.

Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.

At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).

The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.

Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.

Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.

The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State

The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.

The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…

Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…

Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…

The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.

The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.

The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.

The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).

The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.

Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…

Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers

COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.

New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.

Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.

The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.

Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…

The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.

Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…

COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.

Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.

High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.

The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.

The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.

As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…

Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.

Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.

The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment

Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…

64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days

The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations

Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries

CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.

New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…

Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.

Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)

Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible

Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.

COVAX vaccine roll-out

Last update: 17 June 2021 18:30 CET

COVAX has so far shipped over 88 million COVID-19 vaccines to 131 participants

  • The Philippines receive 2.28 million PfizerBioNTech vaccine doses

  • How "camel riders" are helping the COVID-19 vaccine push in Kenya

Learn more

 

What is COVAX?

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the World Health Organization (WHO), alongside key delivery partner UNICEF. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

For any enquiries about the COVAX Facility, please contact covax@gavi.org.

 

COVAX Humanitarian Buffer

The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of ‘last resort’ to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status. Both COVAX Participants and humanitarian agencies can apply for Humanitarian Buffer doses.

 

N.B. While application review, approval, prioritisation and allocation will be undertaken on an ongoing basis by the IASC decision-making body, applicants are advised that shipment of doses is contingent on available supply and successful contracting with manufacturers:

  • Supply constraints affecting the COVAX Facility will also impact the availability of doses to the Humanitarian Buffer.

  • Shipments for humanitarian agencies, including UN organisations, Red Cross and Red Crescent, International and national non-governmental and civil society organisations, are subject to successful conclusion of contracts with manufacturers, including on indemnity and liability-related arrangements.

Applying for the COVAX Humanitarian Buffer

COVAX Humanitarian Buffer applications are for doses, devices and delivery funding, as required. For any questions, or to submit an application, please contact COVAX_Humanitarian_Buffer@gavi.org.

 

Why we need COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

What COVAX offers

Population Doses for at least 20% of countries' populations
Vial Diverse and actively managed portfolio of vaccines
Delivery Vaccines delivered as soon as they are available
Pandemic End the acute phase of the pandemic
Economie Rebuild economies

 

Gavi's role in COVAX

  • COVAX Facility

Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX. The COVAX Facility will make investments across a broad portfolio of promising vaccine candidates (including those being supported by CEPI) to make sure at-risk investment in manufacturing happens now. This means the COVAX Facility, by pooling purchasing power from all countries that participate, will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval. Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries.

Gavi is coordinating the development and implementation of the COVAX AMC, the financing instrument that will support the participation of 92 lower-middle and low-income economies in the COVAX Facility. The COVAX AMC is critical to ensuring equitable access to COVID-19 vaccines, regardless of income level – and requires an urgent investment of US$ 2 billion, from sovereign donors, philanthropies and the private sector, by the end of 2020. The COVAX AMC and associated support to the eligible countries that apply will build on Gavi’s two decades of experience delivering life-saving vaccines to more than half of the world’s population, including in the hardest to reach communities.

  • Country readiness & delivery

Gavi is working with Alliance partners UNICEF and WHO to ensure that the infrastructure is in place, and the technical support available, to make sure COVID-19 vaccines can be safely delivered to all those who need them. Gavi is also part of the health systems work of the ACT-Accelerator effort, focusing on areas where it has expertise and experience, such as cold chain.

Learn more

 

Key COVAX articles

View more

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.

Eswatini received its first batch of 32 000 Oxford-AstraZeneca vaccines in late March. 12 000 came through the COVAX facility and 20,000 through a donation from the Indian Government.

Wondering what you can do to help end the acute phase of the pandemic? Go Give One – is giving everyone everywhere a chance to play their part.

Mastercard, a long-standing partner of Gavi, recently committed US$ 28 million to the Gavi COVAX AMC, to ensure vaccines are accessible to those that needed them the most, no matter where they live. Vaccines Work spoke to Michael Froman to learn…

Some of the world’s wealthiest countries nations have already committed to share doses with lower-income countries through COVAX: as G7 leaders meet this week, other governments must follow suit and share their doses now, because we only have a…

We remain locked in a deadly race with the virus. We will only win when we have created a “variant-proof” world that can keep a lid on the havoc caused by its troublesome mutations.

 

COVAX Facility and COVAX AMC document library

Click below

COVAX documents

17 March 2021

COVAX Pillar: Structure and Principles

9 November 2020 (updated 17 March 2021)

Last updated: 23 Jun 2021

Subscribe to our newsletter